{"transactions":[{"id":2933115,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-23T23:44:03.000Z","date":"2020-12-21","kind":"other","acquired":false,"shares":383411,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a pro rata in-kind distribution of shares of common stock of Denali Therapeutics Inc. from Neuro Line Partners, L.P. (\"Neuro Line\") to limited partners of Neuro Line without consideration, including to an entity controlled by Douglas K. Bratton."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer were held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton had voting and investment power over all securities that were held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may have been deemed to have had a pecuniary interest in a portion of the securities that were held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may have been deemed to have had a pecuniary interest in a portion of the securities that were held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each have been deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-035043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320035043/doc4.xml","form_type":"4"}},{"id":2944570,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-15T21:47:24.000Z","date":"2020-12-14","kind":"sale","acquired":false,"shares":876,"price":81.1281,"value":71068.2156,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.115 to $81.18, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.  In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":383411,"source":{"system":"sec-edgar","filing":"0000899243-20-033903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320033903/doc4.xml","form_type":"4"}},{"id":2944569,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-15T21:47:24.000Z","date":"2020-12-14","kind":"sale","acquired":false,"shares":16949,"price":80.3454,"value":1361774.1846,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.10 to $80.99, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.  In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":384287,"source":{"system":"sec-edgar","filing":"0000899243-20-033903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320033903/doc4.xml","form_type":"4"}},{"id":2944568,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-15T21:47:24.000Z","date":"2020-12-11","kind":"sale","acquired":false,"shares":46799,"price":80.0539,"value":3746442.4661,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.83 to $80.31, inclusive. The reporting persons undertake to provide to Denali Therapeutics Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4) and (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.  In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":401236,"source":{"system":"sec-edgar","filing":"0000899243-20-033903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320033903/doc4.xml","form_type":"4"}},{"id":3096699,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-30T23:17:56.000Z","date":"2020-06-30","kind":"sale","acquired":false,"shares":200,"price":24.34,"value":4868.0,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.  In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":448035,"source":{"system":"sec-edgar","filing":"0000899243-20-018024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320018024/doc4.xml","form_type":"4"}},{"id":3096698,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-30T23:17:56.000Z","date":"2020-06-30","kind":"sale","acquired":false,"shares":45145,"price":24.0056,"value":1083732.812,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.34 to $24.33, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.  In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":448235,"source":{"system":"sec-edgar","filing":"0000899243-20-018024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320018024/doc4.xml","form_type":"4"}},{"id":3096697,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-30T23:17:56.000Z","date":"2020-06-29","kind":"sale","acquired":false,"shares":20771,"price":24.5041,"value":508974.6611,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.36 to $24.76, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.  In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":493380,"source":{"system":"sec-edgar","filing":"0000899243-20-018024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320018024/doc4.xml","form_type":"4"}},{"id":3096696,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-30T23:17:56.000Z","date":"2020-06-29","kind":"sale","acquired":false,"shares":61807,"price":23.8387,"value":1473398.5309,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.36 to $24.355, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.  In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":514151,"source":{"system":"sec-edgar","filing":"0000899243-20-018024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320018024/doc4.xml","form_type":"4"}},{"id":3096695,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-30T23:17:56.000Z","date":"2020-06-26","kind":"sale","acquired":false,"shares":13604,"price":24.6719,"value":335636.5276,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.49 to $24.91, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.  In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":575958,"source":{"system":"sec-edgar","filing":"0000899243-20-018024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320018024/doc4.xml","form_type":"4"}},{"id":3096694,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-30T23:17:56.000Z","date":"2020-06-26","kind":"sale","acquired":false,"shares":108473,"price":23.8441,"value":2586441.0593,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.485 to $24.48, inclusive. The reporting persons undertake to provide to Denali Therapeutics Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6) and (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.  In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":589562,"source":{"system":"sec-edgar","filing":"0000899243-20-018024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320018024/doc4.xml","form_type":"4"}},{"id":3102064,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T21:41:00.000Z","date":"2020-06-23","kind":"sale","acquired":false,"shares":3247,"price":26.1866,"value":85027.8902,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.105 to $26.32, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":698035,"source":{"system":"sec-edgar","filing":"0000899243-20-017498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320017498/doc4.xml","form_type":"4"}},{"id":3102063,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T21:41:00.000Z","date":"2020-06-23","kind":"sale","acquired":false,"shares":16777,"price":25.6864,"value":430940.7328,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.09 to $26.085, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":701282,"source":{"system":"sec-edgar","filing":"0000899243-20-017498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320017498/doc4.xml","form_type":"4"}},{"id":3102062,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T21:41:00.000Z","date":"2020-06-22","kind":"sale","acquired":false,"shares":24683,"price":25.1169,"value":619960.4427,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.94 to $25.34, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":718059,"source":{"system":"sec-edgar","filing":"0000899243-20-017498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320017498/doc4.xml","form_type":"4"}},{"id":3102061,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T21:41:00.000Z","date":"2020-06-22","kind":"sale","acquired":false,"shares":65373,"price":24.6576,"value":1611941.2848,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.94 to $24.93, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":742742,"source":{"system":"sec-edgar","filing":"0000899243-20-017498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320017498/doc4.xml","form_type":"4"}},{"id":3102060,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T21:41:00.000Z","date":"2020-06-19","kind":"sale","acquired":false,"shares":62439,"price":24.998,"value":1560850.122,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.61 to $25.60, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":808115,"source":{"system":"sec-edgar","filing":"0000899243-20-017498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320017498/doc4.xml","form_type":"4"}},{"id":3102059,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T21:41:00.000Z","date":"2020-06-19","kind":"sale","acquired":false,"shares":82481,"price":24.1953,"value":1995652.5393,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.60, inclusive. The reporting persons undertake to provide to Denali Therapeutics Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6), (7) and (8)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":870554,"source":{"system":"sec-edgar","filing":"0000899243-20-017498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924320017498/doc4.xml","form_type":"4"}},{"id":3559422,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":2,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":3,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":4,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-10T01:27:18.000Z","date":"2019-03-25","kind":"other","acquired":false,"shares":158764,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pro rata in-kind distribution of shares of common stock, par value $0.01 per share, (the \"Common Stock\") of Denali Therapeutics Inc. from Neuro Line Partners, L.P. (\"Neuro Line\") to limited partners of Neuro Line without consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares of Common Stock reported in Column 5 are held directly by Neuro Line.  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.  In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":953035,"source":{"system":"sec-edgar","filing":"0000899243-19-010426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000089924319010426/doc4.xml","form_type":"4"}},{"id":4131906,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131905,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":128200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":128200},"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131904,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":743599,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":743599},"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131903,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":1875000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1875000},"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131902,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":2500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2500000},"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131901,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":14499999,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14499999},"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131900,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"purchase","acquired":true,"shares":275000,"price":18,"value":4950000.0,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":19462499,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131899,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":240000,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":1111799,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131898,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":128200,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":871799,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131897,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":743599,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":743599,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131896,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":1875000,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":19187499,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131895,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":2500000,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":17312499,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131894,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":14499999,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":14812499,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}}]}